Relay Therapeutics (RLAY) Gains from Investment Securities (2021 - 2022)

Relay Therapeutics' (RLAY) quarterly Gains from Investment Securities came in at -$4.6 million in Q1 2022, down 649.64% on a QoQ basis from $836000.0 in Q4 2021.

Relay Therapeutics (RLAY) Gains from Investment Securities (2021 - 2022) Analysis & Trends

Relay Therapeutics (RLAY) has 2 years of Gains from Investment Securities data on file, last reported at -$4.6 million in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Relay Therapeutics 3.35 Bn 3.35 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2022 -4.60 Mn
Mar 31, 2022 -4.60 Mn
Dec 31, 2021 836,000.00
Dec 31, 2021 836,000.00